Stocks making the biggest moves midday: Tesla, Enphase Energy, Exxon Mobil and more

Stocks making the biggest moves midday: Tesla, Enphase Energy, Exxon Mobil and more


A Tesla service and sales center is shown in Vista, California, June 3, 2022.

Mike Blake | Reuters

Check out the companies making headlines in midday trading Wednesday.

Tesla, Twitter — Shares of Tesla fell 5.5% after a Tuesday filing confirmed that CEO Elon Musk agreed to buy Twitter for $54.20 per share, the original price he’d agreed upon for the acquisition. Shares of Twitter slumped 1%, taking a breather after surging more than 22% on Tuesday.

Morgan Stanley, Goldman Sachs — Shares of Morgan Stanley and Goldman Sachs dropped 2.3% and 2.8%, respectively, following downgrades from Atlantic Equities. The firm said the two investment banks have few positive catalysts ahead as they continue to deal with macro challenges. Morgan Stanley was downgraded to neutral from overweight, and Goldman Sachs was lowered to underweight from neutral.

Airbnb — Shares of the travel rental company fell 1.5% even after Bernstein initiated the stock as outperform with a price target of $143, indicating an upside of about 30%. The Wall Street firm said Airbnb is on track to become the biggest travel western travel platform over the next five years.

Carnival — Cruise line stocks declined as a group. Shares of Carnival fell 7%, Royal Caribbean Group dropped 3.5%, and Norwegian Cruise Line Holdings declined 3.4%. The group got a boost a day earlier, after Norwegian said it would end all Covid-19 testing and vaccination requirements.

Enphase Energy, Sunrun — Solar stocks declined Wednesday after their rally earlier this week. Shares of Enphase Energy declined 13%, and Sunrun tumbled 9.5%.

Schlumberger — Energy stocks spiked as a group after OPEC+ decided to cut oil output by 2 million barrels a day. Schlumberger advanced 6.4%, Exxon Mobil gained 4.3%, and Phillips 66 rose 3%.

Lamb Weston Holdings — Shares of the food products company climbed 4.7% after Lamb Weston reported large increases in net sales and net income for its fiscal first quarter. Lamb Weston’s adjusted earnings of 75 cents per share beat analyst estimates of 50 cents per share, according to StreetAccount. The Idaho-based company also maintained its full-year outlook despite seeing a volume decline in the quarter.

Lumen Technologies — The tech company’s shares plummeted 10.3% to a 52-week low after Wells Fargo cut its price target on Lumen 56% and downgraded the stock from overweight to equal weight. Wells Fargo said its mass market segment was seeing downsides that put the dividends at risk.

— CNBC’s Alexander Harring, Yun Li, Jesse Pound and Carmen Reinicke contributed reporting.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More